Todos Announces Notice of Allowance From USPTO for
Post# of 1418
(Total Views: 355)
Posted On: 08/30/2023 1:30:17 PM
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid(TM) and Tollovir(TM) Ingredients
Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF) , a medical diagnostics and related solutions company, today announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharma’s patent application entitled "Compounds for Treating a Coronavirus Infection” prosecuted from the groundbreaking work of Dr. Dorit Arad. The Notice of Allowance covers the use of key compounds contained in the ingredients in Tollovid™ and Tollovir™ (NLC-V-01, NLC-001 or 3CL-001). The allowed claims are directed, among other things, to the administration of compounds to a subject to inhibit activity of the 3CL protease, inflammation and autophagy, and to treat coronavirus infection.
The USPTO's assessment pertains solely to patentability, while approvability as a disease treatment falls solely within the jurisdiction of the United States Food & Drug Administration (US FDA). Tollovid, a unique 3CL protease inhibition dietary supplement, is not approved by the US FDA for the diagnosis, treatment, prevention or cure of any disease including COVID, acute and/or chronic coronavirus infections, or Long COVID. Tollovir, an anti-cytokine and 3CL protease inhibitor therapeutic candidate that has successfully completed a Phase 2 clinical trial in the treatment of hospitalized COVID-19 patients, is not approved by the US FDA to diagnose, treat, prevent, or cure any disease including COVID, acute and/or chronic coronavirus infections or Long COVID.
Tollovid and Tollovir are manufactured with distinct raw materials, such that the key ingredients of Tollovir are separate and distinct from the key ingredients in Tollovid, resulting in separate end products from different key raw materials that contain patent pending compounds.
Dr. Dorit Arad, an accomplished visionary and the Founder of CTO at NLC Pharma, has shared her sentiments on this accomplishment, stating, "My life's work has revolved around advancing the science of inhibiting 3CL protease, inflammation, and autophagy within human subjects. I am gratified by the patent allowance which validates the patentability of these crucial aspects inherent in the Tollovid and Tollovir compounds."
“The USPTO granting of this Notice of Allowance marks a major milestone for the Tollovid and Tollovir programs,” said Gerald Commissiong, President & CEO of Todos Medical.
For more information, please visit todosmedical.com . For more information on the Company’s dietary supplement that provides immune support with 3CL protease inhibition, please visit www.mytollovid.com .
https://m.investorshangout.com/recentnews/TOMDF
Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF) , a medical diagnostics and related solutions company, today announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharma’s patent application entitled "Compounds for Treating a Coronavirus Infection” prosecuted from the groundbreaking work of Dr. Dorit Arad. The Notice of Allowance covers the use of key compounds contained in the ingredients in Tollovid™ and Tollovir™ (NLC-V-01, NLC-001 or 3CL-001). The allowed claims are directed, among other things, to the administration of compounds to a subject to inhibit activity of the 3CL protease, inflammation and autophagy, and to treat coronavirus infection.
The USPTO's assessment pertains solely to patentability, while approvability as a disease treatment falls solely within the jurisdiction of the United States Food & Drug Administration (US FDA). Tollovid, a unique 3CL protease inhibition dietary supplement, is not approved by the US FDA for the diagnosis, treatment, prevention or cure of any disease including COVID, acute and/or chronic coronavirus infections, or Long COVID. Tollovir, an anti-cytokine and 3CL protease inhibitor therapeutic candidate that has successfully completed a Phase 2 clinical trial in the treatment of hospitalized COVID-19 patients, is not approved by the US FDA to diagnose, treat, prevent, or cure any disease including COVID, acute and/or chronic coronavirus infections or Long COVID.
Tollovid and Tollovir are manufactured with distinct raw materials, such that the key ingredients of Tollovir are separate and distinct from the key ingredients in Tollovid, resulting in separate end products from different key raw materials that contain patent pending compounds.
Dr. Dorit Arad, an accomplished visionary and the Founder of CTO at NLC Pharma, has shared her sentiments on this accomplishment, stating, "My life's work has revolved around advancing the science of inhibiting 3CL protease, inflammation, and autophagy within human subjects. I am gratified by the patent allowance which validates the patentability of these crucial aspects inherent in the Tollovid and Tollovir compounds."
“The USPTO granting of this Notice of Allowance marks a major milestone for the Tollovid and Tollovir programs,” said Gerald Commissiong, President & CEO of Todos Medical.
For more information, please visit todosmedical.com . For more information on the Company’s dietary supplement that provides immune support with 3CL protease inhibition, please visit www.mytollovid.com .
https://m.investorshangout.com/recentnews/TOMDF
(0)
(0)